Kailera Therapeutics Inc (KLRA) Stock Analysis
Verdict: AVOID
Severe clinical burn and 33% 90-day slide test Kailera's GLP-1 asset potential before late-stage readouts and 2029 revenue.
Investment score: 39/100
Analysis as of
Is Kailera Therapeutics Inc stock worth reviewing? AI model thesis
Kailera Therapeutics is a clinical-stage biopharma developing GLP-1 and multi-agonist metabolic therapies. With $0 in revenue, a -$122.30M FCF burn, and a Q2 2026 earnings miss of 42.5%, the stock is down 33.0% in 90 days to $15.74 (near 52W low of $15.15). Despite strong analyst target consensus ($42.00), heavy cash burn and binary trial risk make it unappealing for risk-managed portfolios.
7-factor investment score
- Valuation: 30/100 (weight 20%)
- Financial Health: 55/100 (weight 15%)
- Technical Momentum: 20/100 (weight 15%)
- Earnings Quality: 35/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 25/100 (weight 15%)
Kailera Therapeutics Inc opportunities and risks
What speaks for KLRA
- KAI-9531 Dual GLP-1/GIP Agonist Pipeline Value
What speaks against KLRA
- Dilutive Secondary Equity Offerings and Cash Burn Accelerations
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| KLRA | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.2% |
| ADMA | 13.3x | 4.3x | 9.7x | 64.7% | 33.0% | 5.2% |
| GENB | n/a | 154.7x | n/a | 75.8% | -950.7% | -6.8% |
| VRDN | n/a | 36.6x | n/a | 99.6% | -544.1% | -12.9% |
| COAG | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.1% |
| ZBIO | n/a | 2078.4x | n/a | -5972.6% | -48438.4% | -10.9% |
| Peer median | n/a | 36.6x | n/a | 64.7% | -544.1% | -6.8% |
Frequently asked questions about Kailera Therapeutics Inc (KLRA)
Is KLRA stock a good investment?
The cached TradeMates AI model rates Kailera Therapeutics Inc as AVOID with an investment score of 39/100. Kailera Therapeutics is a clinical-stage biopharma developing GLP-1 and multi-agonist metabolic therapies. With $0 in revenue, a -$122.30M FCF burn, and a Q2 2026 earnings miss of 42.5%, the stock is down 33.0% in 90 days to $15.74 (near 52W low of $15.15). Despite strong analyst target consensus ($42.00), heavy cash burn and binary trial risk make it unappealing for risk-managed portfolios. This is algorithmic model output, not personal investment advice.
Is KLRA stock a buy?
The TradeMates model verdict for KLRA is AVOID with an investment score of 39/100. Treat this as a model signal to review, not a personal buy recommendation.